The therapeutic potential of psilocybin in anorexia nervosa in young adults

Trial status: Authorised General Anxiety (GAD-2), Patient Health Questionnaire (PHQ-2), Experiences in Close Relationships – (ECR–RS), Life Satisfaction (LS), Positive & Neg Affect (PANAS), Harmony in Life (HILS), Self-compassion (Short SCS), Ten Item Pers Inv (TIPI), AN symptom severity (EDE), Response: A clinically significant improvement in weight and psychological symptoms during the treatment period., Remission: The achievement and maintenance of weight restoration and psychological well-being, with no significant symptoms of anorexia nervosa., Relapse: Defined as a composite outcome during the 6-month follow-up period Incidence of adverse events (AEs) and serious adverse events (SAEs) during the trial period.

General Anxiety (GAD-2), Patient Health Questionnaire (PHQ-2), Experiences in Close Relationships – (ECR–RS), Life Satisfaction (LS), Positive & Neg Affect (PANAS), Harmony in Life (HILS), Self-compassion (Short SCS), Ten Item Pers Inv (TIPI), AN symptom severity (EDE), Response: A clinically significant improvement in weight and psychological symptoms during the treatment period., Remission: The achievement and maintenance of weight restoration and psychological well-being, with no significant symptoms of anorexia nervosa., Relapse: Defined as a composite outcome during the 6-month follow-up period

Age group: 0-17 years, 18-64 years Gender: Female, Male Target enrollment: 40 participants